Thursday, 20 October 2011 00:50
Christopher Henney, Chairman of the Board of Oncothyreon Inc. (Nasdaq: ONTY) and of Anthera Pharmaceuticals (Nasdaq: ANTH) and Vice Chairman of the Board of Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), received this year's Hall of Fame - special recognition of outstanding individual contributions award at the annual Biotech CEO Meeting at Laguna Beach.
Henney, the co founder of Immunex, ICOS and Dendreon corporations was recognized for his contributions to the development of those companies' leading products, Enbrel, Cialis and Provenge, all amongst the industry's most important biopharmaceuticals.
Henney, a native of England, came to the biotech industry from an earlier career as an academic immunologist at Johns Hopkins School of Medicine. He served as the first Head of Immunology at the Fred Hutchinson Cancer Center. Dr. Henney received a Ph.D. in experimental pathology from the University of Birmingham, England, where he also obtained his D.Sc. for contributions in the field of immunology.
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
SOURCE Oncothyreon Inc